Respiratory Syncytial Virus

Baroness Buscombe Excerpts

Thursday 19th January 2023 Lords Chamber

[Lord Markham (Con)]

I can report best on nirsevimab, which has just been licensed, is shown to be 75% to 80% effective in the trials and has the approach of immunising people for six months. I am aware of Pfizer developing a maternal vaccination for whooping cough, which will give the baby immunisation through the mother. The House will also be aware of the recent announcement we made with Moderna on the investment in new R&D facilities here, so that we are at the forefront. I hope the noble Lord can see that we are looking at all these new innovations and will roll them out.

[Baroness Buscombe (Con)]

My Lords, have we not learned some lessons, from Covid and long Covid, of the need for children, babies and all of us to build our immune systems? Long Covid is proving that we have a real problem. I caught this virus from my granddaughter, a baby. I am told that the more she catches these wretched things now, the healthier she will be and the better she will be at putting off some serious diseases later in life. While accepting that high-risk babies obviously need particular regard, is it not right that we should be mindful of continually looking for a vaccine every time a new virus is discovered?

[Lord Markham (Con)]

My noble friend is correct in that, for the vast majority of people—infants in this case—it is mild, flu-like symptoms at most. At the same time, it is responsible for 35,000 hospitalisations and 20 to 30 deaths a year, so it is a serious thing that we need to get on top of. We are looking for the best of both worlds. That 90% of two year-olds will have had RSV and so will have that natural protection is a good thing. But in the most serious cases—the risk groups are those with congenital lung or heart disease or spinal muscular problems—these new treatments really will help and are very important.